We are excited to be hosting Tribe Public's Next Webinar Presentation and Q&A Event which will be held Wednesday, March 3 (8:30 am PT/ 11:30 am ET). Our events are approximately 30 minutes in duration.
David A. Dodd, Chairman, President, CEO & Mark W. Reynolds, CFO of GeoVax Labs (NASDAQ: GOVX) will deliver a presentation titled "Advancing A Unique Broad-based Vaccine Approach To Fighting COVID-19, Ebola & Beyond!" They will be also be available for a 5-10 minute Q&A session at the end of the presentation. Send Questions to email: research@tribepublic.com.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against multiple cancers.